ETFIQData as of Nov 18, 2026. · etfiq.com/funds/ivog

IVOG Fact Sheet: Vanguard S&P Mid-Cap 400 Growth ETF

Share
$132.08
close, Nov 18, 2026

Over the year to Nov 18, 2026, IVOG returned +14.6% in total and charged 0.10% a year.

1-year total return
+14.6%
IJK +14.6% to Nov 18, 2026
Expense ratio
0.10%
a year
Net assets
$1.7bn
on Oct 31, 2026

Growth of $10,000, 1 year

IVOG $11,464 +14.6% · IJK $11,456 +14.6% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month−2.5%
3 months−8.7%
Year to date+9.9%
1 year+14.6%
3 years+48.2%
5 years+27.5%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Okta Inc1.99%
TechnipFMC PLC1.55%
United Therapeutics Corp1.48%
ATI Inc1.30%
XPO Inc1.28%
Tenet Healthcare Corp1.27%
Roku Inc1.18%
nVent Electric PLC1.18%
Royal Gold Inc1.12%
Woodward Inc1.04%

IVOG top ten by weight, 13.4% of the fund, of its 247 equity positions, from the holdings filed for Oct 31, 2026.

Facts

Equity fund · Tracks the S&P MidCap 400 Growth Index · First traded Sep 9, 2010 · Benchmark S&P MidCap 400 Growth Index, measured by IJK, which tracks the same index

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, IVOG Fact Sheet: Vanguard S&P Mid-Cap 400 Growth ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/ivog/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ivog.